Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B cell function and inhibition of the PD-1/PD-L1 pathway

Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of patients with relapsed/refractory or treatment-naïve CLL. Besides directly inhibiting BTK, ibrutinib possesses immunomodulatory properties through targeting multiple signaling pathways. Understanding how th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Kondo, Kayo, Shaim, Hila, Thompson, Philip A., Burger, Jan A., Keating, Michael, Estrov, Zeev, Harris, David, Kim, Ekaterina, Ferrajoli, Alessandra, Daher, May, Basar, Rafet, Muftuoglu, Muharrem, Imahashi, Nobuhiko, Alsuliman, Abdullah, Wierda, William, Jain, Nitin, Liu, Enli, Shpall, Elizabeth J., Rezvani, Katayoun
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6128536/
https://ncbi.nlm.nih.gov/pubmed/28972595
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.304
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados